We also note that even though we did not extensively optimize the dosing and scheduling of the repurposed compounds, 7 out of 14 tested drugs that we predicted to work in concert with anti-CTLA4, indeed showed an additional anti-tumour effect. This evidence concerns the gene CTLA4 and neoplasm.